4 D Molecular Therapeutics Inc stock is traded at $11.25, with a volume of 1,601,017. It is down -8.39% in the last 24 hours and down -12.93% over the past month. 4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
Previous Close:
$12.28
Open:
$12.11
24h Volume:
1,601,017
Relative Volume:
1.64
Market Cap:
$621.50M
Revenue:
$88.24M
Net Income/Loss:
-$160.90M
P/E Ratio:
-
EPS:
-$2.66
Net Cash Flow:
-$129.35M
1W Performance:
-11.97%
1M Performance:
-12.93%
6M Performance:
+15.86%
1Y Performance:
+7.04%
1-Day Range:
$11.16$12.11
1-Week Range:
$11.16$12.44
52-Week Range:
$6.96$16.93
4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile
Name
4 D Molecular Therapeutics IncSector
HealthcareIndustry
BiotechnologyPhone
(510) 505-2680Address
5858 HORTON STREET #455, EMERYVILLE, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS